NASOPHARYNGEAL CANCINOMA (NPC)

This phase 3 trial tests whether adding the drug anlotinib to standard chemoradiation and immunotherapy can help people with high-risk nasopharyngeal cancer live longer without the cancer coming back. About 412 adults aged 18-65 with advanced throat cancer will be randomly assign…

This study tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemoradiation can better shrink tumors and prevent cancer from returning in people with high-risk nasopharyngeal cancer. About 514 adults with advanced throat cancer will be randoml…

This study tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before and after surgery can help people with nasopharyngeal cancer that has come back in the same area. About 53 adults will receive the drug combination, then have minimally invasive surgery to r…

This study compares a shorter course of the drug tislelizumab (given with chemotherapy and radiation) to a longer course in people with advanced nasopharyngeal cancer. The goal is to see if the shorter treatment works just as well at preventing the cancer from coming back or spre…

This study tests whether adding chemotherapy to an immunotherapy drug (adebrelimab) can better control advanced nasopharyngeal cancer in patients who still have signs of the virus (EBV DNA) after standard treatment. About 516 adults aged 18-65 with stage II-III disease will be ra…

This study tests a combination of two drugs, Becotatug vedotin and Pucotenlimab, as a first treatment for people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combo can shrink tumors and delay cancer growth. About 30 adults aged 18-75 with advance…

This study is for people whose nasopharyngeal cancer has come back and cannot be surgically removed. It tests a treatment plan that starts with a mix of an immunotherapy drug (PD-1 antibody) and two chemotherapy drugs, followed by targeted radiation. The goal is to see if this ap…